Capital Management Associates NY acquired a new position in shares of Natus Medical Incorporated (NASDAQ:BABY) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 11,000 shares of the medical equipment provider’s stock, valued at approximately $412,000.

A number of other institutional investors also recently bought and sold shares of the stock. BlackRock Inc. increased its position in Natus Medical by 0.6% during the 2nd quarter. BlackRock Inc. now owns 4,149,535 shares of the medical equipment provider’s stock worth $154,779,000 after purchasing an additional 25,340 shares in the last quarter. Vanguard Group Inc. increased its position in Natus Medical by 2.9% during the 2nd quarter. Vanguard Group Inc. now owns 2,341,546 shares of the medical equipment provider’s stock worth $87,340,000 after purchasing an additional 66,676 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Natus Medical by 10.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,552,938 shares of the medical equipment provider’s stock worth $57,924,000 after purchasing an additional 151,372 shares in the last quarter. Daruma Capital Management LLC grew its holdings in Natus Medical by 13.1% in the 2nd quarter. Daruma Capital Management LLC now owns 1,470,839 shares of the medical equipment provider’s stock valued at $54,862,000 after buying an additional 169,890 shares during the period. Finally, Bank of New York Mellon Corp grew its holdings in Natus Medical by 9.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 973,346 shares of the medical equipment provider’s stock valued at $36,307,000 after buying an additional 86,192 shares during the period. Hedge funds and other institutional investors own 99.53% of the company’s stock.

TRADEMARK VIOLATION WARNING: “11,000 Shares in Natus Medical Incorporated (BABY) Purchased by Capital Management Associates NY” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.dailypolitical.com/2017/11/14/11000-shares-in-natus-medical-incorporated-baby-purchased-by-capital-management-associates-ny.html.

Several analysts have commented on BABY shares. Zacks Investment Research cut Natus Medical from a “hold” rating to a “sell” rating in a report on Friday, July 28th. BidaskClub cut Natus Medical from a “sell” rating to a “strong sell” rating in a report on Thursday, August 24th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. Natus Medical currently has a consensus rating of “Hold” and a consensus price target of $46.50.

In other news, VP Dong Chune Christopher Chung sold 12,642 shares of Natus Medical stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $42.91, for a total value of $542,468.22. Following the transaction, the vice president now directly owns 141,414 shares of the company’s stock, valued at approximately $6,068,074.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Robert A. Gunst sold 4,400 shares of Natus Medical stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $35.17, for a total value of $154,748.00. Following the completion of the transaction, the director now directly owns 50,850 shares in the company, valued at $1,788,394.50. The disclosure for this sale can be found here. Insiders own 5.50% of the company’s stock.

Natus Medical Incorporated (NASDAQ BABY) traded down $0.20 on Tuesday, reaching $40.80. The company’s stock had a trading volume of 223,935 shares, compared to its average volume of 386,220. The company has a quick ratio of 3.36, a current ratio of 4.21 and a debt-to-equity ratio of 0.36. The stock has a market cap of $1,289.78, a PE ratio of 26.71 and a beta of 0.89. Natus Medical Incorporated has a 52 week low of $31.65 and a 52 week high of $43.85.

Natus Medical (NASDAQ:BABY) last posted its quarterly earnings results on Wednesday, October 25th. The medical equipment provider reported $0.40 EPS for the quarter, beating the consensus estimate of $0.38 by $0.02. The company had revenue of $122.60 million during the quarter, compared to analysts’ expectations of $122.41 million. Natus Medical had a positive return on equity of 12.06% and a negative net margin of 0.62%. The firm’s revenue was up 34.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.39 EPS. equities research analysts predict that Natus Medical Incorporated will post 1.74 EPS for the current year.

Natus Medical Company Profile

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Institutional Ownership by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.